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Abstract
Structure and synthesis of Erythropoietin: Erythropoietin (EPO) is a glycoprotein hormone.
Recombinant Erythropoietin (Epoetin): Human recombinant erythropoietin is characterised as a factor which stimu-
lates differentiation and proliferation of erythroid precursor cells, and as a tissue protective factor.
Anti-ischemic effects of recombinant Erythropoietin: Erythropoietin is one of the most perspective humoral agents 
which are involved in the preconditioning phenomenon.
Erythropoietin receptors and signal transduction pathways: Erythropoietin effects on cells through their inter-
connection with erythropoietin receptors, which triggers complex intracellular signal cascades, such as JAK2/STAT 
signaling pathway, phosphatidylinositol 3-kinase (PI3K), protein kinase C, mitogen-activated protein kinase (MAPK), 
and nuclear factor (NF)-κB signaling pathways.
Mechanisms of the effect of Erythropoietin on hematopoietic and non-hematopoietic cells and tissues: In addition 
to regulation of haemopoiesis, erythropoietin mediates bone formation as it has an effect on hematopoietic stem cells 
and osteoblastic niche, and this illustrates connection between the processes of haematopoiesis and osteopoiesis which 
take place in the red bone marrow.
The effect of Erythropoietin on mesenchymal stem cells and process of bone tissue formation: Erythropoietin 
promotes mesenchymal stem cells proliferation, migration and differentiation in osteogenic direction. The evidence 
of which is expression of bone phenotype by cells under the influence of EPO, including activation of bone specific 
transcription factors Runx2, osteocalcin and bone sialoprotein.
Conclusion: Erythropoietin has a pleiotropic effect on various types of cells and tissues. But the mechanisms which are 
involved in the process of bone tissue restoration via erythropoietin are still poorly understood.
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Structure and synthesis of 
Erythropoietin
Erythropoietin (EPO) is a glycoprotein hormone which 
belongs to type I Cytokine Superfamily (Coleman and 
Brines 2004). EPO is most similar to cytokines, which 
modulate growth and inflammation (Erbayraktar et al. 
2003). EPO is made up of about 60% protein and 40% 
carbohydrate (Rölfing 2014). Molecular weight of the 
EPO is 30.4 kDa (Jelkmann 2013).
The feature of erythropoietin is its multifunctionality 
because, depending on conditions, this protein can act as 
cytokine, hormone and growth factor. Erythropoietin real-
izes its cytokine effect through its interaction with specific 
receptors located on the surface of the target cells, which 
leads to the signal transduction from external to internal 
medium of the target cells. Erythropoietin acts as a classic 
hormone because it is synthesized in one organ (intersti-
tial cells of the peritubular capillary bed of the renal cor-
tex in adults or perisinusoidal cells of the liver during the 
embryonic and perinatal period), then it is released into 
the blood flow and effects on remote structures, including 
the hematopoietic system (red blood cells progenitors and 
precursors found in human bone marrow). And, finally, as 
a growth factor, erythropoietin is essential for mature red 
blood cells formation from multipotent progenitor cells 
(Uversky and Redwan 2017).
The gene of human EPO codes the precursor protein 
which includes 193 aminoacidic residues (Lappin et al. 
2002, Sasaki et al. 2000, Vazquez-Mellado et al. 2017). 
Removal of 27-aminoacid sequence results in formation 
of mature protein, which is subjected to the N-glycosyl-
ation at three aspartic residues, O-glycosylation at serine 
residue; C-terminal arginine is removed to create final cir-
culating form which includes 165 aminoacidic residues. 
Thus, mature EPO is heavily glycosylated (Jelkmann 
2007, Ridley et al. 1994, Vazquez-Mellado et al. 2017), 
has three N-linked and one O-linked acidic oligosac-
charide side chains (Jelkmann 2013, Ridley et al. 1994, 
Vazquez-Mellado et al. 2017). Four anti-parallel α-helix-
es (αA, αB, αC and αD in order from N-terminal to C-ter-
minal) with adjacent cycles determine spatial tertiary 
structure of EPO (Desai 2012, Lappin et al. 2002). Gly-
cosylated chains maintain the biological activity of EPO 
and ensure stability of the structure (Maiese et al. 2008, 
Toyoda et al. 2000, Vazquez-Mellado et al. 2017). The 
EPO molecule is hydrophobic and requires presence of 
the disulphide bridges for its activity (Ridley et al. 1994).
EPO production depends on the transcription rate of the 
EPO gene (located in the 7th chromosome). The process of 
EPO gene transcription involves few transcription factors. 
The EPO gene promoter is inhibited by GATA-2 and nucle-
us factor κB (NF-κB), which probably are responsible for a 
decrease in EPO expression during inflammatory diseases 
(Bunn et al. 1998, La Ferla et al. 2002, Jelkmann 2013).
Kidneys are the primary site of EPO production. Dur-
ing hypoxia, the EPO gene expression increases in the 
kidney peritubular fibroblasts via hypoxia-induced tran-
scription factor, and EPO is subsequently released into the 
circulation (Rölfing 2014). Before the birth, the liver is a 
primary site of EPO production, in adults approximately 
10% of EPO is synthesized by the liver (Dame et al. 1998, 
Jelkmann 2007, Rankin et al. 2007, Rölfing 2014, Zanjani 
et al. 1977). Predominant expression of EPO occurs in 
kidneys and liver, though transcripts can be also found in 
other tissues, such as brain, heart, and lungs (Elliott and 
Sinclair 2012).
Recombinant Erythropoietin 
(Epoetin)
Biotechnological achievements have made it possible to 
clone and produce a great amount of human recombinant 
erythropoietin (rhEPO) (Flaharty et al. 1990) and its ana-
logues (erythropoiesis-stimulating agents (ESAs)) (Elliot 
and Sinclair 2012, Jacobs et al. 1985, Rölfing 2014). En-
dogenous erythropoietin and recombinant erythropoietin 
are identical, except for some minor differences in glyco-
sylation (Koury and Bondurant 1992, Rölfing 2014). Hu-
man recombinant erythropoietin was first characterised as 
a hematopoietic factor (Ye et al. 2010). It was shown that 
this substance stimulated differentiation and proliferati-
on of erythroid precursor cells (Broudy et al. 1991, Ye 
et al. 2010). Recombinant forms of erythropoietin are 
epoetin-alfa (human erythropoietin which is produced in 
cell culture using recombinant DNA technology), epoe-
tin-beta (which is a synthetic recombinant form of EPO) 
and long-term acting analogue darbepoetin-alfa (which is 
also a synthetic form of erythropoietin) (Arcasoy 2008, 
Uversky and Redwan 2017). Use of recombinant forms 
of erythropoietin was characterised to treat anaemia du-
ring pregnancy (Sanchez-Gonzalez et al. 2016), chronic 
kidney disease (Tögel et al. 2016) or chemotherapy-indu-
ced anaemia during oncological diseases (Arcasoy 2008, 
Elliot and Sinclair 2012, Suk et al. 2008).
Ubiquitous expression of erythropoietin receptors on 
non-erythroid cells is the evidence that the erythropoietin 
plays a lot of biologically important roles in non-hemato-
poietic tissues (Arcasoy 2008, Arcasoy 2010).
Recombinant erythropoietin was characterized as a tis-
sue protective factor (Elliot and Sinclair 2012, Rocha et 
al. 2015, Vinberg et al. 2015). Protective effect of eryth-
ropoietin is dose-dependent and receptor-dependent. This 
circumstance has resulted in pharmacological synthesis 
of various types of erythropoietin: Asialoerythropoietin 
has half-life under 2 minutes (whereas for erythropoie-
tin this index is approximately 5–10 hours); Carbam-
yl-erythropoietin (CEPO) is characterised by presence of 
a few NH2 groups. It was shown that CEPO has bigger 
protective effect in such injuries, as spinal cord compres-
sion, diabetic neuropathy or experimental autoimmune 
encephalitis without the erythropoiesis stimulation effect 
(Buemi et al. 2009).
Research Results in Pharmacology 5(1): 53–66 55
There were identified some properties of recombinant 
erythropoietin in regulation of genes expression and their 
function similar to vascular endothelial growth factor 
(VEGF), main angiogenic factor (Suk et al. 2008). It is 
known that erythropoietin is able to stimulate prolifera-
tion of endothelial cells in vitro and mobilize endothelial 
progenitor cells from bone marrow (Bahlmann et al. 2003, 
Bahlmann et al. 2004, Heeschen et al. 2003, Klopsch et al. 
2009), increase adhesive and proliferative characteristics of 
circulating endothelial progenitor cells (George et al. 2005, 
Klopsch et al. 2009) and induce neovascularization of is-
chemic tissue in vivo (Ye et al. 2010). Under the influence 
of erythropoietin, embryonic stem cells can differentiate 
into cardiomyocytes; erythropoietin also facilitates prolif-
eration of cardiomyocytes (Broudy et al. 1991, Sachinidis 
et al. 2002, Ye et al. 2010). Erythropoietin is able to in-
fluence differentiation of neuronal stem cells into neuronal 
cells (Chen et al. 2009, Kretz et al. 2005, Ye et al. 2010).
Anti-ischemic effects of 
recombinant Erythropoietin
In a pharmacological aspect, erythropoietin is one of the 
most perspective humoral agents which are involved in 
the preconditioning phenomenon. A number of studies 
showed that erythropoietin has a protective effect on 
ischemia-reperfusion in various organs and tissues (Da-
nilenko 2013). The opportunity of using recombinant 
erythropoietin in suberythropoietic doses is justified for 
pharmacological preconditioning; influence of recombi-
nant erythropoietin on ischemic tissues survival was re-
vealed and it was concluded that this effect was similar to 
that from remote preconditioning (Kolesnik et al. 2010). 
Recombinant human erythropoietin is of increased inte-
rest in regard to pharmaceutical simulation of ischemic 
preconditioning because it proved its efficacy in protecti-
on of heart, brain and liver tissues from pathological in-
fluence of ischemia-reperfusion (Alehin et al. 2015).
Erythropoietin is highly effective in prevention and 
treatment of ischemic-reperfusion-induced acute kidney 
injury. Derivatives of erythropoietin (asialated erythro-
poietin, carbamylated darbepoetin) have nephroprotec-
tive effects (Elagin et al. 2018).
Recombinant erythropoietin was found to stimulate 
neovasculogenesis in ischemic muscle (Kolesnik et al. 
2011, Pokrovskiy et al. 2012).
A possibility of pharmacological correction of is-
chemia and reperfusion injuries of small intestine and liv-
er tissues with recombinant erythropoietin in a suberyth-
rostimulating dose in rats was investigated. It was shown 
that injection of recombinant erythropoietin in a suberyth-
rostimulating dose in rats had a significant effect on mi-
crocirculation recovery both in liver and small intestine 
tissues. Erythropoietin is considered as a preconditioning 
agent which realizes its effect via the early precondition-
ing mechanisms (Alekhin et al. 2011).
Using of recombinant erythropoietin Darbepoetin alpha 
is characterized by development of endothelium- and car-
dioprotective effect (Denisyuk et al. 2015, Denisyuk and 
Pokrovsky 2016, Korokina et al. 2009). In the experiments 
on animals’ (rats’) hearts, it was shown that application of 
erythropoietin led to improved coronary perfusion. This 
effect is caused by activation of endothelial NO synthase 
and Akt (Protein kinase B) activating phosphorylation, 
which leads to long NO-dependent vasodilatation. Some 
evidence was obtained that recombinant erythropoietin is 
characterized by a protective effect in L-NAME-induced 
endothelial disfunction and ischemia of limbs, abdominal 
organs and retina (Denisyuk et al. 2015).
An independent cardioprotective effect of erythropoi-
etin was proven, as well as a decrease in the myocardial 
infarction zone and improvement of heart function in is-
chemia-reperfusion, irrespective of changes in haemoglo-
bin, red blood cell count and oxygen tension in blood. 
Erythropoietin is a trigger of ischemic preconditioning 
and may cause pharmacological preconditioning; realisa-
tion of natural mechanisms of protection from ischemia 
is carried out through the activation of ATP-dependent 
potassium channels and biosynthesis of nitric oxide, 
pharmacological mimetics of preconditioning which in-
duce a reproducible and stable cardioprotective reply and 
which lack any serious side effects (Danilenko 2013). 
Some studies show that decreased apoptosis is one of the 
possible most important mechanism of erythropoietin’s 
protective effect (Danilenko et al. 2012, Danilenko 2013, 
Denisyuk and Pokrovsky 2016, Denisyuk 2016).
Using recombinant erythropoietin leads to a significant 
increase in anti-inflammatory effect (Danilenko et al. 2011).
Erythropoietin receptors and 
signal transduction pathways
Erythropoietin is known to bind to membrane receptors 
(EPOR) localized on the surface of the target cells (Jelk-
mann 2007). EPOR belongs to Class I of Cytokine super-
family receptors, which are characterized by the presen-
ce of extracellular N-terminal sequence. Mature human 
EPOR is a glycoprotein which includes 484 aminoacidic 
residues and 1 N-glycan. Molecular weight of human 
EPOR is 52.6 kDa, and because of glycosylation and 
phosphorylation it increases to 60 kDa (Jelkmann 2007).
In hematopoietic cells, two molecules of erythropoie-
tin receptor (EPOR) form a homodimer (EPOR/EPOR) 
with high affinity to its ligand erythropoietin (Rölfing et 
al. 2014). Binding with erythropoietin induces confor-
mational changes and leads to tight conjunction of two 
monomer EPOR molecules. As a result, Janus kinases 2 
(JAK2) molecules (Witthuhn et al. 1994), which contact 
with EPOR in the juxtamembrane domain, converge and 
subsequently transphosphorylate (Elliott and Sinclair 
2012). Activation of JAK2 leads to phosphorylation of 
a few EPOR tyrosine residues, which serve as sites for 
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signal molecules binding, such as Src homology-2 (SH2) 
domain-containing proteins and signal transducer, and ac-
tivator of transcription (STAT) 1, 3 and 5 (Carter-Su et al. 
2016, Kirito et al. 2002, Klingmuller et al. 1996, Kwon et 
al. 2014, Li et al. 2015, Ma et al. 2016, Rafiee et al. 2005, 
Vazquez-Mellado et al. 2017, van der Kooij et al. 2008, 
Ye et al. 2010). Activated JAK2 also induces signaling 
pathways via nuclear factor kappa B (NF-κB) (Ma et al. 
2016). Erythropoietin is known to be the main activat-
ing factor of JAK2/STAT3 signaling pathway, which is 
confirmed to be launched in blood diseases and cardiac 
cerebral vascular diseases (Chen et al. 2009, Piuhola et al. 
2008, Ye et al. 2010). When STAT3 signaling transduc-
tion pathway is activated, the activated STAT3 transfers 
the signal directly into the nucleus and regulates multi-
ple genes (Ye et al. 2010). STAT5 and NF-κB translocate 
into the nucleus and act as transcription factors for Bcl-2 
(Correia et al. 2015, Ma et al. 2016) and Bcl-xL (Ma et 
al. 2016, Schwartz et al. 2015), which are antiapoptotic 
genes (Ma et al. 2016). In addition to activation of JAK/
STAT pathway, erythropoietin also stimulates other sign-
aling pathways, including phosphatidylinositol-3 kinase/
Akt (PI3K/Akt) pathway, mitogen-activated protein ki-
nase/extracellular signal-related kinase (MAPK/ ERK1/2) 
pathway and protein kinase C, ensuring the survival of 
the cell and its proliferation (Bao et al. 1999, Damen et 
al. 1995, Hiram-Bab et al. 2015, Hiram-Bab et al. 2017, 
Kwon et al. 2014, Vazquez-Mellado et al. 2017). The ef-
fect of erythropoietin is terminated by the influence of 
haematopoietic cell phosphatase (HCP) which catalyzes 
JAK2 dephosphorylation (Jelkmann 2007).
Unlike hematopoietic cells, in non-hematopoietic cells 
erythropoietin carries out its functions through the interac-
tion with a heterodimeric receptor (EPOR/CD131) (Rölf-
ing et al. 2014). In comparison with homodimeric EPOR, 
which is present in the hematopoietic system, the heterod-
imeric receptor is characterised by lower affinity to its li-
gand, erythropoietin. Due to this, for erythropoietin to real-
ize its protective effect towards tissues and other pleiotropic 
effects, a bigger concentration of the hormone is required 
than during erythropoiesis stimulation (Rölfing 2014).
It is known that on the surfaces of the cells which are 
sensitive to erythropoietin, EPOR and a common receptor 
subunit β (βcR), also known as CD131, are co-expressed. 
The common receptor subunit β provides for an increase 
in the binding affinity of the ligand to the receptor complex 
and is also a signal-transducing component common to the 
granulocyte-macrophage colony stimulating factor (GM-
CSF), IL-3 and IL-5 receptors. Furthermore, tissue pro-
tection is known to be realized through this heteroreceptor 
complex containing EPOR and βcR (Brines et al. 2004).
Non-hematopoietic intracellular signaling pathways in-
clude production of nitrogen oxide and signaling through 
JAK2, STAT3/5, PI3K/Akt, as well as MAPK pathways 
(Rölfing et al. 2014). Some functions are activated when 
specific pathways are activated, whereas for erythropoietin 
to exercise its full pleiotropic effect, all signalling intracel-
lular pathways need to be activated (Rölfing et al. 2014).
Mechanisms of effect of 
Erythropoietin on hematopoietic 
and non-hematopoietic cells and 
tissues
The effect of Erythropoietin on hematopoietic tissues
Erythropoietin was first identified as a hormone whose 
main function was to stimulate differentiation of erythroid 
cell precursors in bone marrow into functional erythro-
blasts (Coleman and Brines 2004, Debeljak et al. 2014, 
Flaharty et al. 1990, Ganz 2018, Perreault and Venters 
2018, Ridley et al. 1994, Tojo et al. 2015), which makes 
it possible to regulate delivery of oxygen to the tissues 
(Semenza and Wang 1992). Erythropoietin increases the 
number of developing erythroid precursors and acce-
lerates release of reticulocytes from bone marrow, but 
does not influence on the duration of the cell cycle or the 
number of meioses which take place during the cell dif-
ferentiation (Ridley et al. 1994). Erythropoietin increases 
the pool of cells capable of differentiating into erythroid 
cells. It is an important hormone which determines dif-
ferentiation of cells in the erythroid direction, interacts 
with early-stage (burst forming unit-erythroid, BFU-E) 
and late-stage (colony forming erythroid unit, CFU-E) 
erythroid precursors, cells committed to erythroid diffe-
rentiation. Erythropoietin apparently stimulates prolife-
ration of proerythroblasts and basophilic erythroblasts, 
which are the first cells to be morphologically recognized 
as erythroid elements; however, erythropoietin is not an 
obligatory differentiation growth factor in the erythroid 
direction at this stage (Ridley et al. 1994). Regulation of 
red blood cells production is mediated via presence of a 
specific cellular receptor for erythropoietin on the surface 
of cells (Arcasoy 2008).
The effect of Erythropoietin on non-hematopoietic 
tissues
For a long period of time, there was an opinion that ery-
thropoietin influenced only on erythroid precursor cells 
(Lappin et al. 2002). At present, it is known that erythro-
poietin is a pleiotropic growth factor and, besides its clas-
sic role in facilitating erythropoiesis, this hormone carries 
out a number of biological functions (Wang et al. 2018), 
including activity towards multiple cells and tissues (Co-
leman and Brines 2004, Debeljak et al. 2014, Holstein et 
al. 2011). This hormone is able to stimulate bone tissue 
recovery after damage (Holstein et al. 2007, Holstein et 
al. 2011, Garcia et al. 2011, Klontzas et al. 2016), wound 
healing due to erythropoietin-mediated stimulation of cell 
proliferation and angiogenesis (Gupta and Wish 2017) 
which is related to increased expression of vascular en-
dothelial growth factor (VEGF), endothelial nitric oxi-
de synthase (eNOS) and inducible nitric oxide synthase 
(iNOS) (Holstein et al. 2011). Erythropoietin is known to 
have a neuroprotective effect (Bramlett et al. 2016, Juul 
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and Pet 2015, Liu et al. 2017, Marelli et al. 2016, Modrak 
et al. 2017, Ott et al. 2015) and to provide liver regenera-
tion (Kedarisetty et al. 2015).
Expression of erythropoietin was found in multiple 
tissues and types of cells outside the kidney tissue, in-
cluding astrocytes, neurones, female genital tracts, male 
genitals, mammary glands, placenta trophoblasts, bone 
marrow macrophages and erythroid precursors (Arcasoy 
2010, Bernaudin et al. 1999, Conrad et al. 1996, Juul et al. 
2000, Kobayashi et al. 2002, Magnanti et al. 2001, Marti 
et al. 1996, Masuda et al. 2000, Sato et al. 2000, Stopka et 
al. 1998, Vogt et al. 1989). mRNA of erythropoietin was 
also revealed in liver, spleen, lungs; besides, erythropoi-
etin could be produced in small amounts in these organs 
(Jelkmann 2013). The research results showed that the re-
ceptors for erythropoietin are expressed on various cells 
of the fetus and the adult organism, including cells of cen-
tral nervous system, digestive canal, kidney, muscle tissue 
(smooth, skeletal and cardiac), uterus, retina, pancreas, 
gonads and lungs (Ammarguellat et al. 1996, Anagnostou 
et al. 1994, Arcasoy 2010, Erbayraktar et al. 2003, Grimm 
et al. 2002, Liu et al. 1997, Ogilvie et al. 2000, Shiozawa 
et al. 2010, Westenfelder et al. 1999, Wu et al. 1999). Due 
to this, erythropoietin can influence non-hematopoietic 
cells and tissues (Debeljak et al. 2014).
Thus, it was revealed that erythropoietin, in addition to 
its basic role in the regulation of erythropoiesis in mam-
mals, influences proliferation and apoptosis of various 
non-hematopoietic cells through the erythropoietin recep-
tors (Arcasoy 2008). The characteristic of non-erythropoi-
etic biological effects of erythropoietin and understanding 
the mechanisms of signal activation of the erythropoietin/
erythropoietin receptor systems in non-hematopoietic or-
gans and types of cells are important for future develop-
ment of new methods of applying erythropoietin and its 
derivatives (Arcasoy 2008).
The effect of Erythropoietin on 
mesenchymal stem cells and 
process of bone tissue formation
Mesenchymal stem cells (MSCs) are primary multipotent 
stem cells with an ability of self-renewal and differenti-
ation into multiple cell lines. MSCs have fibroblast-li-
ke morphology and express stromal markers, including 
CD73, CD105, CD29, CD44 and CD90, but not hema-
topoietic cell markers (such as CD34, CD44 and CD45) 
(Chen et al. 2013, Ye et al. 2010).
Bone-marrow-derived mesenchymal stem cells are suit-
able for transplantation and are widely used in tissue engi-
neering and cellular therapy because they are characterised 
by simple selection and obtaining, multipotent potential, 
immunosuppression and stability during autologous trans-
plantation (Li et al. 2017, Rennert et al. 2012, Ye et al. 2010).
However, the population of MSCs in bone marrow is 
not large (about 0.001–0.01% of all nuclear cells), thus it 
is necessary to increase the number of MSCs in culture 
for subsequent use during scientific experiments or clin-
ical application (Ye et al. 2010). Whereas some studies 
showed that MSCs tended to lose pluripotency and pro-
liferative capacity when cultivated in vitro (Banfi et al. 
2000, Digirolamo et al. 1999, Wagner et al. 2008, Ye et 
al. 2010), MSCs are also known to be capable of spon-
taneous differentiation during in vitro passaging in the 
absence of special inducing factors (Deng et al. 2006, Sa-
chinidis et al. 2002, Ye et al. 2010). In this way, instability 
of cultured MSCs and their decreased stemness limit their 
wide application in clinic (Ye et al. 2010).
The indicator of undifferentiated state and multiple differ-
entiation potential of MSCs is the mRNA expression level 
of embryonic transcription factors OCT4, Nanog, Sox2 and 
TERT (Boyer et al. 2005, Greco et al. 2007, Loh et al. 2006, 
Wang et al. 2006, Ye et al. 2010). It was shown that eryth-
ropoietin regulates the mRNA expression of TERT, OCT4, 
Nanog, Sox2 genes (Ye et al. 2010, Saei Arezoumand et al. 
2017), which are linked with a cell differentiation delay. In 
this case, the effect of erythropoietin depends on duration of 
its action and concentration. It is proved that erythropoietin 
could maintain MSCs in undifferentiated state for 12 hours 
at a concentration of 5 U/ml (Ye et al. 2010).
Erythropoietin is also known to promote MSCs prolifera-
tion (Minguell et al. 2001, Ye et al. 2010, Zheng et al. 2009). 
Thus, influencing proliferation, erythropoietin is able to in-
crease the number of MSCs while preserving their multiple 
differentiation potential, to improve MSCs expansion in cell 
culture and to maintain culture in vitro (Ye et al. 2010).
Despite the achievements in transplantation of 
bone-marrow-derived mesenchymal stem cells, only a tiny 
fraction of transplanted cells migrates to the target sites. 
This is why it is vital to develop a strategy of more effective 
delivery of MSCs to appropriate structures (Ye et al. 2010). 
It is known that erythropoietin activates a directed migra-
tion of bone-marrow-derived mesenchymal stem cells into 
the organs which were damaged, for example, kidneys 
and heart (Lin et al. 2008, Liu et al. 2013, Vazquez-Mel-
lado et al. 2017). Erythropoietin promotes mobilization of 
bone-marrow-derived mesenchymal stem cells by increas-
ing the stromal cell-derived factor-1 (SDF-1) chemokine 
levels (Satoh et al. 2006, Vazquez-Mellado et al. 2017).
In addition, the important problem of applying MSCs 
in tissue engineering is their low viability and functional-
ity, as well as their potential capacity to differentiate after 
transplantation. The majority of MSCs undergo apoptosis 
after transplantation. This is why improving MSCs viabil-
ity and functionality is necessary to enhance their potential 
application efficiency. A few strategies aiming at improv-
ing the ability of MSCs to form tissues have been studied, 
including those with applying growth factors, overexpres-
sion of regulatory genes by stem cells and with improv-
ing scaffolds biomaterials. All the approaches used were 
connected with activation of PI3K/Akt signaling pathway. 
This pathway plays key regulatory roles in MSCs survival, 
proliferation, migration, angiogenesis, cytokine produc-
tion and differentiation processes (Chen et al. 2013).
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The effect of Erythropoietin on osteogenic differentia-
tion of MSCs
MSCs are able to differentiate into the osseous, cartila-
ginous and adipose tissue lineages after stimulation in 
certain conditions. When being cultivated in the presence 
of glucocorticoid dexamethasone, ascorbic acid and be-
ta-glycerophosphate (factors of osteogenic differentiati-
on), MSCs differentiate in osteogenic direction and form 
bone-like nodules with mineralized extracellular matrix 
containing hydroxyapatite. One of the potential pathways 
of signaling transduction which can participate in regu-
lation of proliferation and differentiation of MSCs in os-
teogenic direction is MAP kinase pathway. Members of 
MAP kinase family are extracellular signal-regulated ki-
nases (ERK1 and ERK2), c-Jun N-terminal kinase (JNK), 
which is also known as stress-activated protein kinase, and 
p38-reactivating kinase (p38 RK or simply p38). Transfor-
ming growth factor-beta stimulates ERK and p38 and acts 
as a physiological regulator of osteoblasts differentiation 
and bone tissue remodelling by regulation and coordinati-
on of osteoblasts and osteoclasts activity. It was found out 
that differentiation of cells in osteoinductive culture me-
dium activates ERK2, JNK2 and p38 in time-dependent 
manner. ERK2 is activated via phosphorylation during 
differentiation of cells (Jaiswal et al. 2000). Elevated acti-
vity of NF-κB (which belongs to the Rel transcription fac-
tor family) in human mesenchymal stem cells was found 
to stimulate differentiation of cells in osteogenic direction, 
whereas decreased NF-κB signaling does not prevent the 
osteogenic differentiation (Hess et al. 2009).
It was shown that microRNA (miRNA) promotes os-
teogenic differentiation via gene regulation, for example 
miR-2861 maximizes the Runx2 activity (Meng et al. 
2015). It is known that PI3K/Akt and β-catenin pathways 
are able to regulate bone development. In this case, in-
creased levels of β-catenin lead to enhancement of Runx-
2 expression and finally facilitated bone formation. There 
is evidence that miR-21 can regulate PI3K/Akt pathway, 
and also regulates β-catenin pathway (Meng et al. 2015).
BMP-2 and BMP-4 factors are known to stimulate 
MSCs differentiation in osteogenic direction. Moreover, 
MSCs, which produce BMP-2, improve bone tissue repair 
in the sites of defects (Levy et al. 2010).
Activation of STAT proteins, which are inactive cytoplas-
mic transcription factors, occurs as a result of stimulation 
of a variety of receptor types, and is usually accompanied 
by STAT tyrosine and serine phosphorylation. Members of 
the JAK tyrosine kinase family usually mediate STAT ty-
rosine phosphorylation, which leads to activation of STAT, 
its dimerization and translocation into nucleus. Transcrip-
tional activity of STAT is significantly regulated by serine 
phosphorylation, which usually leads to transcription of 
proliferation-related genes (Levy et al. 2010).
The role of JAK-STAT signaling in MSCs is not prop-
erly studied yet; perhaps JAK-STAT signaling turns on 
in response to the influence of BMP-2 and BMP-4 (Levy 
et al. 2010).
Based on pleiotropic effects of erythropoietin on bone 
tissue, this hormone is attractive for increasing efficiency 
of bone tissue repair (Omlor et al. 2016). However, there 
have been a few studies to investigate the influence of 
erythropoietin on bone tissue repair in vivo (Bozlar et al. 
2006, Garcia et al. 2011, Holstein et al. 2007, Holstein 
et al. 2011, Omlor et al. 2016, Rölfing et al. 2012, Shio-
zawa et al. 2010, Sun et al. 2012). At present, the effect 
of erythropoietin on bone tissue is not fully understood 
(Balaian et al. 2018).
A positive effect of erythropoietin on differentiation of 
mesenchymal stem cells in osteogenic direction attracts 
a significant interest (Wang et al. 2018). It is known that 
mesenchymal stem cells immediately after fracture mi-
grate to site of injury and differentiate into osteoblasts 
preceding the bone regeneration (Nair et al. 2013).
Most scientific papers note that erythropoietin triggers 
differentiation of mesenchymal stem cells into osteoblasts 
in vitro (Balaian et al. 2018, Kim et al. 2011, Li et al. 
2015, Nair et al. 2013, Shiozawa et al. 2010).
On the surface of human MSCs, there are EPOR and 
CD131 receptors, which form EPO heterodimer receptor 
(EPOR/CD131) (Brines et al. 2004, Rölfing et al. 2014, 
Ye et al. 2010, Zwezdaryk et al. 2007). According to data 
obtained by Rölfing et al. (2014), there is no exclusive 
intracellular pathway responsible for the osteogenic dif-
ferentiation of erythropoietin-stimulated MSCs (Rölfing 
et al. 2014). It is known that osteogenic effect of erythro-
poietin on the mesenchymal stem cells is realized through 
the mammalian target of rapamycin (mTOR), JAK2 and 
PI3K signaling pathways (Rölfing et al. 2014).
It was shown that PI3K/Akt pathway is important in the 
process of MSCs differentiation into different cell types. 
However, the role of the pathway is complicated because 
of the opposite effects. PI3K/Akt signaling pathway reg-
ulates proliferation of cells, apoptosis, differentiation and 
migration. The factors which can stimulate the pathway 
activation include various growth hormones, cytokines 
and other molecules (Chen et al. 2013). The key enzyme of 
the pathway is PI3K, which converts phosphatidylinositol 
4,5-biphosphate into phosphatidylinositol 3,4,5-triphos-
phate, which binds Akt and 3-phosphoinositide-dependent 
protein kinase 1 (PDK1), and allows PDK1 to phosphoryl-
ate Akt. Class 1А PI3K consists of two subunits: p110 cat-
alytic subunit and p85 regulatory subunit. There are four 
isoforms of p110 subunit: p110-alpha, -beta, -gamma and 
–sigma and three isoforms of p85 subunit: p85-alpha, -beta 
and -gamma. The main target protein of the PI3K pathway 
is Akt. There are three isoforms of Akt: Akt1, Akt2, Akt3. 
Activation of Akt triggers a cascade of responses which 
regulate the cell functions. For instance, Akt regulates mi-
gration of cells by means of Rac1 and rhoA, increases via-
bility through bcl-2, elevates angiogenesis via VEGF, and 
enhances proliferation by activation of mammalian target 
of rapamycin (Chen et al. 2013).
Activation of PI3K/Akt signaling pathway in MSCs is 
applied both in cellular therapy and in tissue engineering 
(Chen et al. 2013).
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It is proved that the ability of MSCs to secrete cytokines 
is regulated by means of activity of PI3K/Akt signaling 
pathway. In this case, MSCs are able to secrete a number 
of cytokines which can regulate other cells and contrib-
ute to tissue recovery. These cytokines include vascular 
endothelial growth factor, fibroblast growth factor (FGF), 
monocyte chemoattractant protein-1, hepatocyte growth 
factor (HGF), insulin-like growth factor 1 (IGF-1), stro-
mal cell-derived factor 1 (SDF-1), and thrombopoietin. 
Overexpression of Akt in MSCs increases expression of 
genes VEGF, FGF-2, HGF and IGF-1 and thus enhances 
secretion of these cytokines. These cytokines influence 
MSCs, increasing their functionality. For example, MSCs 
are able to express receptor to HGF, c-Met (tyrosine-pro-
tein kinase Met or hepatocyte growth factor receptor 
(HGFR)). HGF at a concentration of 20 ng/ml promotes 
osteogenic differentiation by activating c-Met, Akt path-
ways and enhanced expression of the cell-cycle inhibitor 
p27 and osteogenic transcription factors Runx2 and Os-
terix, whereas at high concentrations (100 ng/ml), HGF 
promotes proliferation and suppresses osteogenic differ-
entiation by activating the ERK1/2 pathway and inhibit-
ing the Akt pathway (Chen et al. 2013).
IGF-1 is found to be expressed in MSCs to increase 
osteogenesis for further bone repair. The mechanism 
includes activation of insulin receptor substrate-1 and 
phosphatidylinositol-3-kinase signaling pathway (IRS1-
PI3K). Also, IGF-1 can activate the MAPK pathway. 
Some studies show that inhibition of MAPK increases 
rather than decreases the rate of osteogenesis (Higuchi 
et al. 2002, Osyczka and Leboy 2005, Payne et al. 2010, 
Wang et al. 2012), proving that the PI3K/Akt pathway 
plays a key role in IGF-induced osteogenesis. It was 
shown that mechanically induced activation of Akt also 
increases the rate of osteogenesis. There are also oppo-
site data about the role of the PI3K/Akt pathway in the 
process of osteogenesis, according to which, imatinib 
stimulates osteogenesis by inhibiting platelet-derived 
growth factor receptors/PI3K/Akt (PDGFR/PI3K/Akt) 
signaling in MSCs. However, the reason of this phenom-
enon is not completely understood yet. It is known that 
BMP-2 enhances osteogenesis by activating the PI3K/
Akt pathway. At present, a number of signaling pathways 
are known to be involved in the process of cell differenti-
ation in certain direction (Chen et al. 2013, Higuchi et al. 
2002, Osyczka and Leboy 2005, Payne et al. 2010, Wang 
et al. 2012).
Erythropoietin is known to stimulate bone tissue for-
mation and to increase the number of osteoblasts in vivo 
(Balaian et al. 2018, Mihmanli et al. 2009, Rolfing et al. 
2012, Sun et al. 2012), especially if the ephrinB2/EphB4 
signaling pathway is activated (Balaian et al. 2018, Li et al. 
2015,). Erythropoietin regulates expression of EphB4 re-
ceptor of bone marrow mesenchymal stem cells (Balaian 
et al. 2018). Interaction of ephrinB2 with EphB4 receptor 
influencing erythropoietin-activated MSCs, triggers dif-
ferentiation of cells (Balaian et al. 2018). Erythropoietin 
enhances osteoblast activity through the EphB4 signaling 
pathway, and also increases the number of ephrinB2-ex-
pressed osteoclasts but decreases their resorption activity. 
The signals activated by erythropoietin through ephrinB2/
EphB4 result in bone formation (Balaian et al. 2018).
Erythropoietin was found to act in collaboration with 
ephrinB2 and to induce osteoblast differentiation, but it 
can also influence this process through other potential 
mechanisms (Balaian et al. 2018). In the mouse cell line 
RAW264.7, erythropoietin significantly increases expres-
sion of Nfatc1, which is an obligatory transcription factor 
for osteoclastogenesis and regulates differentiation and 
fusion of osteoclasts. Moreover, erythropoietin signif-
icantly decreases expression of Mmp9 and Ctsk, which 
are involved in osteoclast-mediated resorption of organic 
components of the bone (Balaian et al. 2018). Further-
more, erythropoietin enhances expression of ephrinB2 on 
the cell line RAW264.7, which can indicate that erythro-
poietin increases the number of osteoclasts which are less 
capable of bone tissue resorption, but express a higher 
level of ephrinB2 (Balaian et al. 2018).
Erythropoietin can stimulate bone tissue formation due 
to increased expression of vascular endothelial growth 
factor (Holstein et al. 2011).
It was revealed that erythropoietin activates hemato-
poietic stem cells to produce BMP factors (BMP2, 
BMP6). In addition, it was discovered that erythropoietin 
influences directly on bone marrow mesenchymal stem 
cells and induces their differentiation in osteogenic di-
rection (Kim et al. 2011, Shiozawa et al. 2010). It is im-
portant that in in vivo conditions erythropoietin mediates 
bone formation by influencing simultaneously on both 
hematopoietic stem cells and the osteoblast niche. Thus, 
erythropoietin regulates bone formation directly and indi-
rectly, which illustrates a link between the hematopoiesis 
and osteopoiesis processes in bone marrow (McGee et al. 
2012, Shiozawa et al. 2010).
The evidence of the fact that erythropoietin causes dif-
ferentiation of bone marrow mesenchymal stem cells in os-
teogenic direction is bone phenotype expression by cells, 
including activation of the bone-specific transcription 
factor Runx2, osteocalcin (OCN) and bone sialoprotein 
(BSP) under the influence of erythropoietin. Moreover, 
erythropoietin mediates an increase in mineral accumula-
tion by the cell cultures and enhanced expression of alka-
line phosphatase (ALP) (Shiozawa et al. 2010).
For erythropoietin-mediated osteoblast differentiation 
of human mesenchymal stem cells, the mTOR signal-
ing pathway needs to be activated (Kim et al. 2011). It 
was also found out that erythropoietin in a combination 
with receptor activator of nuclear factor kappa-B ligand 
(RANKL) increased the number of osteoclasts formed 
from mouse marrow mononuclear cells (mMMCs) and 
mouse macrophage cell line RAW264.7. However, 
erythropoietin inhibits osteoclasts activity by decreasing 
cathepsin K regulation in mTOR-independent manner 
(Kim et al. 2011). During osteoblastogenesis, mTOR sig-
naling may influence proliferation and differentiation of 
osteoblasts (Kim et al. 2011).
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The effect of Erythropoietin on angiogenesis
It is well known that osteogenesis and angiogenesis are in-
terconnected processes which are both required for bone 
formation (Wu et al. 2014). Angiogenesis is a complex 
process of new blood vessels formation from pre-existing 
ones. The process of angiogenesis includes several va-
rious stages: production and release of angiogenic factors, 
binding with endothelial cell receptors and subsequent ac-
tivation of proliferation, directed migration, extracellular 
matrix remodelling, preparation and stabilization of the 
vessels (Buemi et al. 2009).
Erythropoietin takes part in regulation of angiogene-
sis processes including new blood vessels formation from 
pre-existing ones. Physiological angiogenesis occurs 
actively in developing embryo, in female reproductive 
organs to maintain cyclic tissue renewal, and in wound 
healing (Arcasoy 2008). The role of erythropoietin is 
described as that of a pro-angiogenic factor comparable 
with classical pro-angiogenic factors, such as vascular en-
dothelial growth factor and basic fibroblast growth factor 
(bFGF) (Zwezdaryk et al. 2007).
Expression of erythropoietin receptors on the various 
types of vascular endothelial cells is connected with the 
ability of erythropoietin to stimulate migration and pro-
liferation of endothelial cells (Arcasoy 2008). One of the 
supposed mechanisms of erythropoietin-mediated stim-
ulation of tissue neo-vascularisation is mobilization of 
bone marrow endothelial precursor cells into the circu-
latory bed (Arcasoy 2008, Bahlmann et al. 2004, George 
et al. 2005, Heeschen et al. 2003, Satoh et al. 2006, 
Vazquez-Mellado et al. 2017).
Human mesenchymal stem cells derived from bone mar-
row are known to express erythropoietin receptors and can 
promote angiogenesis following an erythropoietin treat-
ment. Thus, human MSCs promote angiogenesis not only 
by direct participating in the process like endothelial cells 
which form new vessels, but also by secretion and recruit-
ing of the components which are necessary for this process 
(Liu et al. 2011, Liu et al. 2013, Zwezdaryk et al. 2007).
Conclusions
Erythropoietin has the pleiotropic effect on multiple num-
ber of cells and tissues; it also influences the processes of 
remodelling and recovery of bone tissue. It is known that 
the effects of erythropoietin on bone tissue are linked with 
increased osteogenesis, osteoclastogenesis and angioge-
nesis. At the same moment, the mechanisms involved in 
the process of bone tissue build-up via erythropoietin are 
still not fully understood.
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